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In patients with chronic bronchitis a four week
trial with inhaled steroids does not
attenuate airway inflammation
D. LOPPOW, M. B. SCHLEISS, F. KANNIESS, C. TAUBE, R. A. JO¨RRES AND H. MAGNUSSEN
Krankenhaus Grosshansdorf, Zentrum fu¨r Pneumologie und Thoraxchirurgie, D-22927 Grosshansdorf, Germany
Systemic corticosteroids have been recommended as a therapeutic option in patients with moderate to severe
COPD. In an early stage of the disease, i.e. chronic bronchitis with mild or no airflow obstruction, a trial with
inhaled steroids could reveal potential benefits, particularly in terms of a modulation of airway inflammation.
We therefore investigated the effect of inhaled fluticasone (1000 mg day71) on markers of airway inflammation in
19 patients with chronic bronchitis (mean+SEM FEV1, 83?4+3?0% predicted; FEV1/VC, 67?5+2?4%) in a double-
blind, cross-over, placebo-controlled manner. Visits were performed before and after two 4-week treatment periods,
separated by a 4-week washout period. Lung function, the concentration of exhaled nitric oxide, differential cell
counts in induced sputum and the number of cells positive for iNOS, as well as the levels of LDH, ECP, neutrophil
elastase and IL-8 in sputum supernatants were determined.
Although the total cell number decreased significantly after fluticasone (geometric mean 12?3 vs. 7?76106/ml;
P50?05) it was not significantly different from the change observed after placebo (14?2 vs. 10?66106/ml; n.s.).
None of the other parameters showed statistically significant changes after fluticasone or placebo and the results did
not depend on the presence of airway hyperresponsiveness.
We conclude that in patients with chronic bronchitis short-term treatment with inhaled corticosterids did not
improve lung function or inflammatory parameters to an extent which was statistically significant as compared to
spontaneous variability.
Key words: chronic bronchitis; chronic airway obstruction; inhaled glucocorticosteroids; fluticasone; inducible nitric
oxide synthase (iNOS); exhaled nitric oxide (NO); induced sputum.
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Currently evidence is available that steroid treatment may
be effective in patients with COPD (1,2), and a short course
of systemic corticosteroids has been recommended to test
for reversibility of symptoms, lung function and airway
inflammation (3–5). Early intervention in a chronic disease,
such as chronic bronchitis with or without airflow obstruc-
tion, appears to be a possible method to prevent an
unfavourable course of the disease (6). In this respect,Received 30 May 2000 and accepted in revised form 25 August
2000.
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as they produce less side-effects than oral corticosteroids.
Therefore, anti-inflammatory treatment has been taken
into consideration in COPD, in particular the use of inhaled
corticosteroids, in addition to bronchodilator therapy.
However, a number of studies suggest that corticosteroids
do not markedly improve the clinical state or the course of
the disease (7–14). Some of them included an analysis of
inflammatory markers, such as exhaled NO (15,16), sputum
composition, or the number of sputum cells positive for
inducible nitric oxide synthase (iNOS) (17), as the key
enzyme for the production of exhaled NO (18). In asthma
there is evidence that the level of exhaled NO is associated
with airway hyperresponsiveness (19), whereby the exhaled
NO is known to be highly sensitive to inhaled corticoster-
oids (20). Noteworthy enough, in patients with COPD the
presence of airway hyperresponsiveness appears to be
associated with a poor long-term prognosis (21). Until
now, however, the role of NO in patients with chronic# 2001 HARCOURT PUBLISHERS LTD
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sponsiveness, is unknown (15).
Therefore we studied the effect of a 4-week treatment
with inhaled fluticasone (1000mg day71) on lung function,
markers of airway inflammation in induced sputum, and
exhaled NO in patients with chronic bronchitis, most of
them showing airway hyperresponsiveness in the absence of
marked airway obstruction.
Material and methods
SUBJECTS
Nineteen patients (13 male/6 female) with chronic bron-
chitis, who were smokers or ex-smokers (420 pack-years),
were included into the study (Table 1). Mean (SEM) FEV1
was 83?4+3?0% pred and mean (SEM) FEV1/VC
67?5+2?4%. The patients’ diagnosis was established
following American Thoracic Society (ATS) guidelines
(22) and chronic bronchitis was defined through cough
and sputum production. According to European Respira-
tory Society (ERS) guidelines (23), two patients had no
airway obstruction (FEV1/VC 88%), 14 patients mild
obstruction (FEV1 70% pred and FEV1/VC588%), and
three moderate obstruction (FEV1570% pred and FEV1/
VC588%). Fourteen patients showed airway hyperrespon-TABLE 1. Subjects’ characteristics
No. Sex Age
(years)
Height
(cm)
Pack-
years
1 M 57 169 61
2 M 33 171 26
3 M 55 176 70
4 M 61 176 80
5 M 63 171 30
6 F 55 168 53
7 F 53 162 30
8 M 67 170 27
9 F 66 160 37
10 F 58 162 70
11 F 53 175 53
12 F 47 173 20
13 M 31 193 21
14 M 47 180 30
15 M 54 174 40
16 M 58 176 70
17 M 77 172 50
18 M 56 180 100
19 F 59 159 39
Mean 55 172 48
SEM 2 2 5
#PC20FEV1: concentration of methacholine required to produce
*geometric mean and standard error of mean (SEM).siveness, as indicated by a provocative concentration of
methacholine (PC20FEV1) producing a 20% fall in FEV1,
below 8mgml71 (24) and six patients showed a positive
skin prick test against at least one common airborne
allergen (Table 1).
None of the patients had used inhaled or systemic
corticosteroids within the 3 months preceding the study.
Nicotine, n-methylxanthines (or food containing these
compounds) and short-acting b2-adrenoreceptor agonists
were withheld for at least 4 h before each test. None of the
patients had experienced a respiratory tract infection within
the 4 weeks immediately before the screening visit. The
study was approved by the local ethics committee and all
patients gave their informed written consent.
STUDY PROTOCOL
The study was designed as a double-blind, cross-over,
placebo-controlled trial. In the first screening visit the
patient’s history was taken, and a physical examination,
baseline lung function measurement, skin prick test and
methacholine inhalation challenge were performed. Blood
was obtained by venous punction for the determination of
total IgE and standard cell differentiation. In the second
screening visit (448 h after the first screening visit), exhaled
NO was measured and sputum induction was performed.FEV1
(% pred)
FEV1/VC
(%)
PC20FEV1
#
(mgml71)
Atopy
73?4 53?3 0?31 7
69?6 69?7 0?61 þ
79?4 77?6 32?00 þ
72?7 89?9 32?00 7
76?7 53?7 0?40 7
77?0 61?8 1?39 7
93?3 64?0 1?31 7
110?0 64?3 0?76 þ
100?0 67?9 19?99 þ
86?2 65?9 0?97 þ
100?0 67?0 3?02 7
89?6 64?3 2?34 7
74?3 64?4 1?21 7
77?7 94?1 14?48 7
80?4 68?2 4?76 þ
64?8 58?3 1?34 7
67?0 63?3 0?35 7
89?8 69?0 15?43 7
102?0 66?1 2?21 7
83?4 67?5 *2?43
3?0 2?4 *1?05
a 20% fall in FEV1;
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begun, with either fluticasone 1000 mg day71 or placebo in
random order; treatment periods were separated by a 4-
week washout interval. Immediately before and after each
of the two treatment periods, test visits were performed. On
each of these visits, physical examination, venous blood
puncture, lung function testing, NO measurement and
sputum induction were performed.
LUNG FUNCTION
Lung function was measured using a spirometer (Master-
scope, Jaeger, Wu¨rzburg, Germany) and forced expiratory
volume in 1 sec (FEV1) as well as vital capacity (VC) were
assessed according to ERS guidelines (25). At least two
measurements were performed. For analysis, the highest
value of FEV1 achieved within two acceptable manoeuvres
and the corresponding VC were chosen.
EXHALED NO
According to the approach of Silkoff et al. (26) and ERS
guidelines (27), patients expired against a resistance which
led to vellum closure. Specifically, they were instructed to
perform a rapid deep expiration through the nose, to fit to
the mouth piece at the end of the expiration and to perform
a rapid inspiration of clean air (51 ppb NO) through the
mouth with the nose closed. After the end of inspiration,
the nose was opened again and patients expired while
maintaining a pressure of 20 mbar over ambient pressure.
Pressure was measured by an electronic transducer (GDH
12 A, Greisinger GmbH, Regenstauf, Germany) which
allowed the patients to control their breathing via a display.
Using this method, different expiratory flow rates were
achieved by chosing different resistors, which were made
from stainless steel or copper and corresponded to target
flow rates of 33, 48, 69, 140 and 207ml sec71 at 20mbar.
Between the mouthpiece and resistance, air was sampled
through a Teflon tube into a rapid NOA 280 nitric oxide
analyzer (Sievers Instruments Inc., Boulder, CO, U.S.A.).
Signals were fed into a personal computer to determine NO
plateau values. The NO analyser was checked regularly
using certified NO calibration gas (Messer-Griesheim,
GmbH, Krefeld, Germany). For final data analysis, NO
values at flow rate of 50ml sec71 were derived by
interpolation through a curve that fitted the data points.
INDUCED SPUTUM
Before sputum induction, patients inhaled 200 mg salbuta-
mol from a metered-dose inhaler. To detect potential
bronchoconstriction, lung function was measured before
and every 5min during the procedure. Patients inhaled
hypertonic saline from an ultrasonic nebulizer [NE-U12,
Omron, Tokyo, Japan; nominal output 3mlmin71, mean
(+SD) delivered amount 1?72+0?2mlmin71, mass median
diameter 4?9mm] within three consecutive 10min periods.
Samples produced after the first (3% saline), during and
after the second (4% saline), and during and after the third(5% saline) 10min inhalation period were processed
separately and pooled values were derived afterwards
(28–31). To produce sputum, patients were asked to rinse
their mouth thoroughly, blow their nose, swallow water
and then expectorate the sputum onto a plastic petri dish.
Sputum samples were kept at 48C and were processed either
during the induction procedure or immediately afterwards.
SPUTUM PROCESSING
Under an inverted microscope adequate plugs of sputum
were selected to reduce contamination with saliva (28). As
is common, plugs were defined as the more dense and viscid
parts (28–30) and considered to be adequate when origin
from the lower respiratory tract was assured by the
presence of non-squamous cells and low or absent
squamous cell contamination. We aimed at selecting all
the plugs from the saliva.
The weight of the selected plugs was determined and
twice their volume of sputolysin (6?5mM dithiothreitol,
Calbiochem, Bad Soden, Germany) was added. After
incubation at 378C for 15min and repeated mixing of the
samples during incubation, PBS was added to the samples
to achieve a 20-fold final dilution. Then samples were
centrifuged at 600 g and 48C and supernatants were
collected. One aliquot was used to determine the level of
lactate dehydrogenase (LDH) before freezing; the remain-
ing material was stored at 7808C until further analysis.
Cells were resuspended in PBS/BSA (1%), cell counts were
assessed in a haemocytometer, viability was determined by
trypan blue exclusion, and a portion of 20 000 to 40 000
cells was used to prepare cytospins for differential cell
counts and immunocytochemistry (see below).
ANALYSIS OF SPUTUM
Differential cell counts were assessed by two observers from
400–500 non-squamous cells on coded Giemsa-stained
cytospin slides (32). Results were expressed as percentage
of non-squamous cells. For the presentation of cell
differentials, average values of the percentages observed
within the three consecutive inhalation periods were
computed. The total cell numbers of samples were taken
as weighting factors in order to derive percentages that were
equivalent to those of pooled samples.
Fluid phase parameters were analysed in 20-fold diluted
samples, which were pooled according the weight of the
separate samples; the concentration of the original sample
was calculated from this dilution. LDH was determined by
an automated photometrical method (COBAS MIRA-
Analyser, Roche, Basel, Switzerland) based on the rate of
NADH oxidation. ECP was analysed by the ECP CAP
FEIA (Pharmacia, Uppsala, Sweden), elastase by the
PMN-Elastase Immunoassay (Merck, Darmstadt, Ger-
many) and IL-8 by the PeliKine Compact human IL-8
ELISA kit (CLB, Amsterdam, The Netherlands). All
photometrically achieved data (Dynatech MR5000) were
calculated by BioLinx 2?20 software (Dynatech, Chantilli,
U.S.A.).
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oxide synthase) and the appropriate isotype control was
performed on cytospin preparations of pooled samples.
These samples were prepared from aliquots of the three
separate samples taking into account their total cell
numbers. We used a monoclonal mouse anti-human iNOS
antibody (Transduction Laboratories, via Dianova, Ham-
burg, Germany) or mouse IgG2a as well as the EnVision
signal amplifying system. NewFuchsin substrate solution
(DAKO, Hamburg, Germany) and Mayers haemalaun
counterstaining were used. A total of 400 non-sqamous
cells were counted for leukocytes which were either positive
or negative for iNOS or the isotype control antibody,
respectively. Results were expressed as percentages of
macrophages, neutrophils and eosinophils that were posi-
tive for iNOS minus the respective percentages that were
positive in control slides (background). As a control for
potential selective cell loss during the staining procedure,
cell differentials from these slides were compared with those
of standard cytospin slides computed as described above.
STATISTICAL METHODS
To fulfill the requirement of normal distribution, it was
necessary to log-transform data for all parameters, with the
exception of FEV1 and FEV1/VC. Correspondingly, mean
values and standard errors are given either as geometric
values (in case of transformation) or arithmetic values.
Baseline values (screening visit 2) and values measured
before both treatment periods were compared to each otherTable 2. Lung function, exhaled NO, and sputum composition
Baseline pre
FEV1 (% pred) 81?7+2?7 80?5+3
FEV1/VC (%) 67?5+1?7 67?5+2
Exhaled NO (ppb){ 15?6 (1?2) 14?1 (1
Blood eosinophils (%) 2?2 (1?1) 2?3 (1
Induced sputum
Macrophages (%) 41?3 (1?1) 38?3 (1
Neutrophils (%) 46?0 (1?1) 49?3 (1
Eosinophils (%) 1?3 (1?3) 1?3 (1
Lymphocytes (%) 0?9 (1?2) 1?1 (1
Total cell count (106ml71) 11?5 (1?2) 14?2 (1
LDH (IU l71) 40?0 (1?2) 48?4 (1
ECP (mg l71) 211 (1?2) 282 (1
Elastase (mg l71) 668 (1?2) 762 (1
IL-8 (mg l71) 24?2 (1?2) 33?2 (1
iNOSþmacrophages (%) 6?6 (1?2) 5?7 (1
iNOSþneutrophils (%) 1?4 (1?3) 1?6 (1
Geometric mean values and SEM (in parentheses) are given, e
given. }statistically significant at the level P50?05, {plateau c
50ml sec-1.by repeated-measures ANOVA. All other statistical com-
parisons were performed by the paired t-test. Significance
was assumed for P5 0?05.
Results
None of the parameters showed statistically significant
differences between baseline values and the values measured
before the two treatment periods. Furthermore, there were
no statistically significant changes after placebo treatment.
This was true regarding FEV1, FEV1/VC, the level of
exhaled NO, the percentage of peripheral blood eosino-
phils, the total number of sputum cells, the percentages of
macrophages, neutrophils, eosinophils and lymphocytes in
induced sputum, the concentrations of LDH, ECP,
neutrophil elastase and IL-8 in sputum supernatants as
well as the expression of iNOS in sputum macrophages and
neutrophils (Table 2). The same was true after fluticasone
treatment (Fig. 1), except for total cell number in induced
sputum, which decreased statistically significantly
(P50?05) (Table 2). Concomitantly, the total number of
neutrophils decreased, and this decrease was statistically
significant (P=0?024) too. The effects however, were not
significant when compared to the changes observed after
placebo.
Fourteen of the 19 patients demonstrated airway
hyperresponsiveness to inhaled methacholine. When these
patients were analysed separately, pooled total cell numbersat baseline, and before and after treatment periods
Placebo Verum
post pre post
?0 81?6+2?7 79?9+2?9 81?6+3?6
?1 68?6+2?1 66?4+2?0 67?5+2?1
?1) 13?4 (1?1) 12?8 (1?2) 12?4 (1?1)
?1) 2?1 (1?2) 2?3 (1?1) 2?1 (1?1)
?1) 42?5 (1?1) 39?4 (1?1) 43?6 (1?1)
?1) 50?8 (1?1) 49?1 (1?1) 45?1 (1?1)
?3) 1?0 (1?4) 1?1 (1?3) 0?8 (1?4)
?2) 0?9 (1?2) 0?9 (1?1) 0?9 (1?2)
?2) 10?6 (1?2) 12?3 (1?2) 7?7 (1?1)}
?2) 41?2 (1?2) 42?5 (1?2) 44?0 (1?1)
?3) 204 (1?3) 251 (1?2) 199 (1?2)
?2) 851 (1?2) 718 (1?2) 710 (1?2)
?1) 26?0 (1?2) 30?6 (1?1) 27?9 (1?1)
?3) 5?8 (1?4) 4?5 (1?3) 5?8 (1?2)
?4) 1?6 (1?3) 1?6 (1?3) 1?3 (1?4)
xcept for FEV1 and FEV1/VC, where arithmetic values are
oncentration of exhaled NO at an expiratory flow rate of
FIG. 1. Mean values (SEM) of FEV1 (a), the level exhaled NO (b), and the percentages of sputum eosinophils (c) and
neutrophils (d) before and after 4 weeks of treatment with inhaled fluticasone (1000 g day71).
INHALED STEROIDS AND AIRWAY INFLAMMATION IN CHRONIC BRONCHITIS 119differed statistically significantly (P5 0?05) between pre-
and post-placebo visits; this parameter was not different in
the patients without airway hyperresponsiveness (n=5).
There were no other statistically significant differences
between these two subgroups of patients.
Discussion
Our data demonstrate that in patients with chronic
bronchitis short-term treatment with inhaled corticoster-
oids did not significantly improve lung function or
attenuate airway inflammation as indicated by the cellular
composition of induced sputum, fluid phase markers, the
level of exhaled NO and the expression of iNOS in sputum
cells.
All patients had an extensive smoking history and
reported respiratory symptoms, and most of them showed
a slight reduction in baseline lung function (22,23). In
addition, 74% of patients were hyperresponsive to metha-
choline, in line with previous data, where airway hyperre-
sponsiveness was found in 66% of patients with mild to
moderate COPD (6). Baseline values as well as changes
induced by corticosteroid treatment did not differ between
patients with and without airway hyperresponsiveness.
Furthermore, the number of sputum eosinophils was low
in both groups. These findings rendered it unlikely that the
patients recruited for the study had asthma as a con-
comitant disease. This was also excluded by the detailed
clinical examination and history at inclusion.
Elevated numbers of sputum neutrophils have been
demonstrated repeatedly in patients with COPD (31,33).
In accordance with this, we found increased total cell
numbers and percentages of neutrophils as compared toprevious data obtained in normal subjects using the same
methods (29,30). However, the percentage of neutrophils
was smaller than that reported by Peleman et al. (34),
possibly due to the fact that the patients enrolled in our
study had less severe disease. It is known that the
percentages of sputum neutrophils correlate with the
impairment in lung function (33).
A sample size of 19 subjects within a cross-over design
has sucient power to detect an effect of about the same
size as the variability of the data. As most subjects showed
airway hyperresponsiveness, and corticosteroids are highly
effective in patients with asthma and airway hyperrespon-
siveness, we consider the power of our study to be sucient
to reveal effects of a clinically relevant size. It is clear that
the detection of minor effects that might be relevant for
long-term prognosis would have required a much larger
sample size.
After 4 weeks of treatment with fluticasone, we found a
reduction in total cell number which was, however, not
significantly different from that observed after placebo.
Until now it has not been clarified whether inhaled
corticosteroids have an impact on airway inflammation in
patients with COPD (13,33,35). Confalonieri et al. (2)
observed a reduction in absolute cell counts as well as
percentages of sputum neutrophils in 34 patients with stable
mild to moderate COPD after 8 weeks of therapy with
inhaled beclomethasone 1500mg day71. However, the
percentages of neutrophils which they observed at baseline
were rather high (73%) as compared with our data (49%).
This may at least partially explain the difference in the effect
of inhaled steroids. Also in our study the absolute numbers
of neutrophils slightly decreased after treatment as a
consequence of the fact that their percentage remained
constant but that total cell number decreased. It may be
120 D. LOPPOW ET AL.noted that other studies, even in patients with more severe
COPD, did not find changes in neutrophil numbers after
corticosteroid treatment (10,36).
In all of the patients studied, the levels of exhaled NO
were low as compared to those reported in patients with
asthma (15,19). They were in a similar range as that
observed in patients with more severe COPD (37), taking
into account the differences in the methods of NO
measurement. Exhaled NO, which is known to be increased
in patients with asthma, appears to be associated with
eosinophilic inflammation within the airways (19). In
patients with COPD, eosinophil numbers are usually low
and airway eosinophilia occurs mainly during exacerba-
tions (38). Under these circumstances, eosinophilia may be
a predictor for a positive response to corticosteroids
(39,40). This finding is in line with observations that the
exhaled NO is elevated during exacerbations (41). In the
patients included by us, eosinophil numbers were low
irrespective of the presence of airway hyperresponsiveness,
and the percentages of eosinophils were not further reduced
by corticosteroid treatment. Similarly, the low baseline
values of exhaled NO could be the cause that their levels did
not change during the treatment period.
The transcription of iNOS is controlled via NF-kB,
which is strongly affected by glucocorticosteroids (42).
Therefore, we wondered whether the measurement of iNOS
expression, as a marker of airway inflammation, would
supply a sensitive technique to monitor the effects of
inhaled corticosteroids. However, we did not find statisti-
cally significant changes in the percentages of iNOS-
positive macrophages or neutrophils. This could be due to
the low numbers of iNOS-positive macrophages, which we
observed in our samples. As compared to the data of
Rutgers et al. (17), the percentage of sputum macrophages
stained for iNOS was just half of their value. However, the
comparison is dicult, in particular as it remains unclear
whether these authors subtracted background levels
assessed by isotype controls or corrected for a potential
selective cell loss during the staining procedure. Within our
data, it was the subtraction of the inevitable background
noise which led to the relatively low numbers of iNOS-
positive cells.
In conclusion, our data demonstrated that in patients
with chronic bronchitis a 4-week treatment with fluticasone
1000 mg day71 did not lead to statistically significant
changes in lung function, the level of exhaled NO, the
cellular composition of induced sputum, the concentration
of selected fluid phase markers, or the percentages of iNOS-
positive cells in sputum. Therefore, these patients appear
not to benefit from a short-term treatment with inhaled
corticosteroids in terms of non-invasive markers of airway
inflammation.
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